Safety of disease-modifying drugs for multiple sclerosis in pregnancy: Current challenges and future considerations for effective pharmacovigilance

Expert Review of Neurotherapeutics

Volumn 13, Issue 3, 2013, Pages 251-261

  Lu, Ellen ^a   Wang, Bing Wei ^a   Guimond, Colleen ^a   Synnes, Anne ^a   Sadovnick, A Dessa ^a   Dahlgren, Leanne ^a   Traboulsee, Anthony ^a   Tremlett, Helen ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

birth; breastfeeding; disease modifying drugs; multiple sclerosis; pregnancy; safety

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; FINGOLIMOD; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; TERIFLUNOMIDE;

ABORTION; ARTICLE; BREAST FEEDING; CLINICAL TRIAL (TOPIC); CONCEPTION; CONGENITAL MALFORMATION; CONTRACEPTION; DRUG EXCRETION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EXPERIMENTAL GUINEA PIG; EXPERIMENTAL MONKEY; EXPERIMENTAL RAT; FEMALE; FETOTOXICITY; FETUS GROWTH; FETUS MALFORMATION; HUMAN; INTRAUTERINE GROWTH RETARDATION; LACTATION; LOW BIRTH WEIGHT; MEDICAL ETHICS; METHODOLOGY; MULTIPLE SCLEROSIS; NEWBORN DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PERINATAL DEVELOPMENT; PHYSICIAN; PREGNANT WOMAN; PREMATURE LABOR; PRENATAL EXPOSURE; SIDE EFFECT; SPONTANEOUS ABORTION; TERATOGENICITY; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; PHARMACOVIGILANCE; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84874601625     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.13.12     Document Type: Article

References (67)

1. Compston A, Coles A. Multiple sclerosis. Lancet 372(9648), 1502-1517 (2008).
2. Frohman EM, Havrdova E, Lublin F et al. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch. Neurol. 63(4), 614-619 (2006).
3. Pittock SJ, Weinshenker BG, Noseworthy JH et al. Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch. Neurol. 63(4), 611-614 (2006).
4. Shirani A, Zhao Y, Karim ME et al. Association between use of interferon β and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 308(3), 247-256 (2012).
5. Buck D, Hemmer B. Treatment of multiple sclerosis: current concepts and future perspectives. J. Neurol. 258(10), 1747-1762 (2011).
6. Tsui A, Lee MA. Multiple sclerosis and pregnancy. Curr. Opin. Obstet. Gynecol. 23(6), 435-439 (2011).
7. Lu E, Wang BW, Guimond C, Synnes A, Sadovnick AD, Tremlett H. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology 79, 1130-1135 (2012).
8. Borisow N, Döring A, Pfueller CF, Paul F, Dörr J, Hellwig K. Expert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancy. EPMA J. 3(1), 9 (2012).
9. Finkelsztejn A, Brooks JB, Paschoal FM Jr, Fragoso YD. What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of the literature. BJOG 118(7), 790-797 (2011).
10. Ferrero S, Esposito F, Pretta S, Ragni N. Fetal risks related to the treatment of multiple sclerosis during pregnancy and breastfeeding. Expert Rev. Neurother. 6(12), 1823-1831 (2006).
11. Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: therapeutic considerations. J. Neurol. doi:10.1007/s00415-012-6653-9 (2012) (Epub ahead of print).
12. Amato MP, Portaccio E, Ghezzi A et al.; MS Study Group of the Italian Neurological Society. Pregnancy and fetal outcomes after interferon-b exposure in multiple sclerosis. Neurology 75(20), 1794-1802 (2010).
13. Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult. Scler. 15(9), 1037-1042 (2009).
14. Salminen HJ, Leggett H, Boggild M. Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes. J. Neurol. 257(12), 2020-2023 (2010).
15. Fragoso YD, Finkelsztejn A, Comini-Frota ER et al. Pregnancy and multiple sclerosis: the initial results from a Brazilian database. Arq. Neuropsiquiatr. 67(3A), 657-660 (2009).
16. Fragoso YD, Finkelsztejn A, Kaimen-Maciel DR et al. Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series. CNS Drugs 24(11), 969-976 (2010).
17. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult. Scler. 17(8), 958-963 (2011).
18. Vukusic S, Hutchinson M, Hours M et al.; Pregnancy In Multiple Sclerosis Group. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 127(Pt 6), 1353-1360 (2004).
19. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T; Pregnancy in Multiple Sclerosis Group. Rate of pregnancy-related relapse in multiple sclerosis. N. Engl. J. Med. 339(5), 285-291 (1998).
20. Portaccio E, Ghezzi A, Hakiki B et al.; MS Study Group of the Italian Neurological Society. Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology 77(2), 145-150 (2011).
21. Neuteboom RF, Hintzen RQ. Breast-feeding, postpartum and prepregnancy disease activity in multiple sclerosis. Neurology 76(17), 1532; author reply 1532-1532; author reply 1533 (2011).
22. Langer-Gould A, Huang SM, Gupta R et al. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch. Neurol. 66(8), 958-963 (2009).
23. Sayre MR, O'Connor RE, Atkins DL et al. Part 2: evidence evaluation and management of potential or perceived conflicts of interest: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 122(18 Suppl. 3), S657-S664 (2010).
24. Strong C. How should risks and benefits be balanced in research involving pregnant women and fetuses? IRB 33(6), 1-5 (2011).
25. Boskovic R, Wide R, Wolpin J, Bauer DJ, Koren G. The reproductive effects of β interferon therapy in pregnancy: a longitudinal cohort. Neurology 65(6), 807-811 (2005).
26. Patti F, Cavallaro T, Lo Fermo S et al. Is in utero early-exposure to interferon β a risk factor for pregnancy outcomes in multiple sclerosis? J. Neurol. 255(8), 1250-1253 (2008).
27. Fernández Liguori N, Klajn D, Acion L et al. Epidemiological characteristics of pregnancy, delivery, and birth outcome in women with multiple sclerosis in Argentina (EMEMAR study). Mult. Scler. 15(5), 555-562 (2009).
28. Hellwig K, Haghikia A, Gold R. Parenthood and immunomodulation in patients with multiple sclerosis. J. Neurol. 257(4), 580-583 (2010).
29. Sandberg-Wollheim M, Alteri E, Moraga MS, Kornmann G. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon β-1a therapy. Mult. Scler. 17(4), 423-430 (2011).
30. Lu E, Dahlgren L, Sadovnick A, Sayao A, Synnes A, Tremlett H. Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs. Mult. Scler. 18(4), 460-467 (2012).
31. Sandberg-Wollheim M, Frank D, Goodwin TM et al. Pregnancy outcomes during treatment with interferon β-1a in patients with multiple sclerosis. Neurology 65(6), 802-806 (2005).
32. De Las Heras V, De Andrés C, Téllez N, Tintoré M; EMPATIE Study Group. Pregnancy in multiple sclerosis patients treated with immunomodulators prior to or during part of the pregnancy: a descriptive study in the Spanish population. Mult. Scler. 13(8), 981-984 (2007).
33. Finkelsztejn A, Fragoso YD, Ferreira ML et al. The Brazilian database on pregnancy in multiple sclerosis. Clin. Neurol. Neurosurg. 113(4), 277-280 (2011).
34. Bastian LA, Piscitelli JT. Is this patient pregnant? Can you reliably rule in or rule out early pregnancy by clinical examination? JAMA 278(7), 586-591 (1997).
35. Corsello G, Giuffrè M. Congenital malformations. J. Matern. Fetal Neonatal Med. 25(Suppl. 1), 25-29 (2012).
36. Daw JR, Mintzes B, Law MR, Hanley GE, Morgan SG. Prescription drug use in pregnancy: a retrospective, populationbased study in British Columbia, Canada (2001-2006). Clin. Ther. 34(1), 239-249 (2012).
37. Ban L, Tata LJ, West J, Fiaschi L, Gibson JE. Live and non-live pregnancy outcomes among women with depression and anxiety: a population-based study. PLoS ONE 7(8), e43462 (2012).
38. Andersen AB, Erichsen R, Farkas DK, Mehnert F, Ehrenstein V, Sørensen HT. Prenatal exposure to acid-suppressive drugs and the risk of childhood asthma: a population-based Danish cohort study. Aliment. Pharmacol. Ther. 35(10), 1190-1198 (2012).
39. Kieler H, Artama M, Engeland A et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 344, d8012 (2012).
40. Marrie RA, Yu BN, Leung S et al. The utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study. Neuroepidemiology 40(2), 85-92 (2012).
41. Kang JH, Chen YH, Lin HC. Comorbidities amongst patients with multiple sclerosis: a population-based controlled study. Eur. J. Neurol. 17(9), 1215-1219 (2010).
42. Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. High frequency of adverse health behaviors in multiple sclerosis. Mult. Scler. 15(1), 105-113 (2009).
43. Misra DP, Caldwell C, Young AA Jr, Abelson S. Do fathers matter? Paternal contributions to birth outcomes and racial disparities. Am. J. Obstet. Gynecol. 202(2), 99-100 (2010).
44. Shah PS; Knowledge Synthesis Group on determinants of preterm/low birthweight births. Paternal factors and low birthweight, preterm, and small for gestational age births: a systematic review. Am. J. Obstet. Gynecol. 202(2), 103-123 (2010).
45. Neuhaus O, Kieseler BC, Hartung HP. Pharmacokinetics and pharmacodynamics of the interferon-βs, glatiramer acetate, and mitoxantrone in multiple sclerosis. J. Neurol. Sci. 259, 27-37 (2007).
46. Bernick SJ, Kane S. Drug transfer to the fetus and to the breastfeeding infant: what do we know? Curr. Drug Deliv. 9(4), 350-355 (2012).
47. Dhib-Jalbut S, Marks S. Interferon-β mechanisms of action in multiple sclerosis. Neurology 74(Suppl. 1), S17-S24 (2010).
48. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays. Proc. Natl Acad. Sci. USA 95(26), 15623-15628 (1998).
49. Moore KL, Persaud TVN. Before We Are Born: Essentials of Embryology and Birth Defects (7th Edition). Saunders/Elsevier, PA, USA (2008).
50. Vollmer T, Stewart T, Baxter N. Mitoxantrone and cytotoxic drugs' mechanisms of action. Neurology 74(Suppl. 1), S41-S46 (2010).
51. Briggs GG, Freeman RK, Yaffe SJ. Mitoxantrone. In: Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Lippincott Williams & Wilkins, PA, USA (2008).
52. Meistrich ML, Wilson G, Mathur K et al. Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease. J. Clin. Oncol. 15(12), 3488-3495 (1997).
53. Ronni T, Melén K, Malygin A, Julkunen I. Control of IFN-inducible MxA gene expression in human cells. J. Immunol. 150(5), 1715-1726 (1993).
54. Buhimschi CS, Weiner CP. Medications in pregnancy and lactation: part 1. Teratology. Obstet. Gynecol. 113(1), 166-188 (2009).
55. Hodge LS, Tracy TS. Alterations in drug disposition during pregnancy: implications for drug therapy. Expert Opin. Drug Metab. Toxicol. 3(4), 557-571 (2007).
56. Goldkind SF, Sahin L, Gallauresi B. Enrolling pregnant women in research-lessons from the H1N1 influenza pandemic. N. Engl. J. Med. 362, 24), 2241-2243 (2010).
57. Battino D, Tomson T. Management of epilepsy during pregnancy. Drugs 67(18), 2727-2746 (2007).
58. Hale TW, Siddiqui AA, Baker TE. Transfer of interferon b-1a into human breastmilk. Breastfeed. Med. 7(2), 123-125 (2012).
59. Hellwig K, Haghikia A, Rockhoff M, Gold R. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther. Adv. Neurol. Disord. 5(5), 247-253 (2012).
60. Stuart M, Bergstrom L. Pregnancy and multiple sclerosis. J. Midwifery Womens Health 56(1), 41-47 (2011).
61. Miller AE, Rustgi S, Farrell C. Use of glatiramer acetate during pregnancy: offering women a choice. Mult. Scler. 18(Suppl. 4), P733 (2012).
62. Giannini M, Portaccio E, Ghezzi A et al. Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol. 12, 124 (2012).
63. Cristiano LM, Bozic C, Bloomgren G. Preliminary evaluation of pregnancy outcomes from the Tysabri (natalizumab) pregnancy exposure registry. Mult. Scler. 17(Suppl. 10), S457 (2011).
64. De Santis M, Straface G, Cavaliere AF, Rosati P, Batocchi AP, Caruso A. The first case of mitoxantrone exposure in early pregnancy. Neurotoxicology 28(3), 696-697 (2007).
65. Hellwig K, Schimrigk S, Chan A, Epplen J, Gold R. A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis. J. Neurol. Sci. 307(1-2), 164-165 (2011).
66. Geissbuhler Y, Butzkueven H, Hernandez-Diaz S et al. Pregnancy outcomes from fingolimod clinical trials and post-marketing experience and the need for a multinational Gilenya™ (fingolimod) Pregnancy Exposure Registry in multiple sclerosis. Mult. Scler. 18(Suppl. 4), P141 (2012).
67. Kieseier B, Benamor M, Benzerdjeb H, Stuve O. Pregnancy outcomes from the teriflunomide clinical development programme: retrospective analysis of the teriflunomide clinical trial database. Mult. Scler. 18(Suppl. 4), P737 (2012).